Pfizer says CHANTIX/CHAMPIX study met primary, secondary endpoints Pfizer announced the completion of a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of CHANTIX®/CHAMPIX® 1 mg BID in comparison to placebo for smoking cessation in patients with a past or present diagnosis of Major Depressive Disorder. The study met its primary and secondary efficacy endpoints. Subjects in the varenicline group had a higher likelihood of quitting at week 12 (primary endpoint) and at week 52 (key secondary endpoint). In addition, psychiatric scales included for safety assessments did not show a difference between varenicline and placebo.
News For PFE From The Last 14 Days
Check below for free stories on PFE the last two weeks.
Subscribe for More Information